How weight-loss medications work

A current map of the medicines people ask about

The table below is a status map, checked on 3 October 2026. It deliberately separates an approved product from a development program. “Not verified” describes a limit of this review; it is not proof that no document could exist elsewhere. Check the linked regulator or sponsor record before making a current decision.

Status sources: US Wegovy label, EU Wegovy record, EU Mounjaro record, FDA Foundayo approval, September CHMP agenda, FDA investigational-product concerns, September CagriSema sponsor update, and FDA survodutide warning evidence. The table is not a comparison of individual suitability or a complete inventory of obesity treatments.

Approval, availability, and coverage are also separate questions. A regulator decision does not tell you whether a local pharmacy has stock, whether your insurer covers a product, or whether it fits your budget. Verify those practical details through the appropriate local sources. The table intentionally makes no price or reimbursement claim, because an undated advertised offer cannot stand in for the terms that apply to an individual.

Three documents, three different jobs

A regulator-issued label describes an approved product, its uses, and important safety conditions. A trial paper describes how a study was conducted and what it found. A sponsor announcement describes what the developer chooses to communicate about its program. None should silently take the place of the others.

For example, a trial paper may test a particular injectable formulation at a defined dose schedule. A later approval may concern a different presentation. The old trial remains useful evidence for its original question, but it is not automatically the study of the new presentation. Similarly, a positive Phase 3 result can be important without changing a product’s legal status.

When researching a treatment, save the documents in three separate lines: current approved product information; the trial most relevant to your question; and any recent announcement awaiting a full paper or decision. This is an original reading workflow. It prevents a submission headline from being mistaken for permission to prescribe, and helps you notice when the sources disagree about the time frame.

What a mechanism can explain

A receptor is a biological target. The mechanism describes how a molecule interacts with a pathway, but a clinical decision needs measured outcomes in people. Appetite, blood glucose, weight, physical function, and cardiovascular events are different outcomes. Even when a treatment affects several of them, the evidence for each may come from different populations and studies.

That distinction is especially useful for a new combination. There can be a plausible reason to combine two pathways without proof that the combination improves every outcome, has fewer adverse effects, or suits every patient. Those conclusions need their own data. Ask which claim is mechanistic, which was measured in a randomized study, and which remains a hypothesis.

Descriptions such as “triple agonist” can be technically accurate while still being poor purchasing advice. The number does not tell you whether the medicine has an approved indication for you, whether a relevant health outcome was measured, or whether the risks are acceptable. A careful explanation should move from the target to the evidence rather than stopping at an impressive name.

Build a comparison around your actual question

A comparison becomes useful when it is specific. “Which treatment has the largest trial average?” is a research-reading question. “Which option has evidence for adults with my medical history and is feasible to continue?” is a care question. It may require several types of information, including evidence that is not expressed as weight loss.

Consider two invented readers. One wants help interpreting new obesity-trial results. The other already has a cardiovascular condition and wants to understand a proposed treatment. They may be reading about the same molecule but need different studies. Their priorities cannot be reduced to a single league table. These are illustrative scenarios, not eligibility assessments.

For a written comparison, use columns for exact product, country, approved use, relevant population, main measured outcome, important restrictions, practical demands, and unresolved questions. Leave a cell blank when you have not verified it. A blank is more honest and useful than filling it with a plausible guess from another product.

Route and frequency are practical details, not shortcuts

The current records include both oral and injectable products. Foundayo is a daily oral tablet; the Wegovy record includes weekly injection and daily tablets. That is enough to show why “pills versus injections” does not describe a single pair of treatments. Product-specific administration instructions still differ. Foundayo prescribing information and EMA Wegovy record.

A person who travels frequently, has an irregular schedule, or relies on help with medicines should discuss those circumstances. Ask a pharmacist to explain the actual instructions rather than choosing a route on the assumption that it is automatically easier. This guide does not convert doses, replace a missed-dose instruction, or select an administration routine.

Bring up storage, obtaining a continuing supply, and the effect of other medicines as practical questions. Do not improvise an alternative schedule when access changes. A treatment plan should include a way to obtain advice for interruptions, instead of treating the first prescription as the entire decision.

Safety is more than the most common side effect

A common adverse effect and a contraindication are different kinds of information. A symptom may affect whether treatment is tolerable; a contraindication can rule out use in a specified situation. The label is the starting document, and the clinician or pharmacist helps interpret it in light of your history. FDA’s benefit-risk guidance.

Prepare a complete list of medicines and supplements, relevant past reactions, and planned procedures. Ask how to contact the care team, what requires timely assessment, and when the next review will occur. A social-media account describing mild symptoms cannot establish that your symptoms are harmless or that the same advice fits your situation.

The approved US labels cited here contain important restrictions and warnings; this article does not reproduce every one. A short overview should never create the impression that risks have been cleared just because a few were mentioned. Keep the exact current product information available for the consultation.

Nutrition and function belong in the follow-up

Reduced appetite raises a practical question: can the person still maintain an adequate food pattern and daily function? A multisociety advisory discusses nutritional support and activity during GLP-1-based treatment. It also relies partly on evidence from broader weight-management research, so an expert recommendation should not be described as a direct trial of every specific medicine. Nutrition advisory.

Useful observations include which meals have become difficult, whether food variety has narrowed, and whether ordinary activities feel harder. A dietitian can review intake; a qualified activity professional can help with movement; a clinician can assess symptoms and treatment. A single protein number or a supplement does not replace those different roles.

An original follow-up note can have four columns: what improved, what became harder, what changed in access or routine, and what question needs professional advice. This format does not diagnose a problem. It makes the treatment experience easier to describe without turning each weigh-in into the whole assessment.

Plan for uncertainty and changes in access

Ask what will happen if benefit is smaller than expected, treatment is not tolerable, or supply and cost change. These are ordinary possibilities to plan for, not reasons to assume failure. The important feature is a review process that can respond to new information rather than a promise that the initial choice will always remain best.

Write down which claims remain unanswered. Examples include long-term comparative outcomes, evidence in a population not represented in the pivotal study, or the status of a newly reported product. Keeping an unanswered question visible is more useful than answering it with another person’s experience. New evidence can then be attached to the right question when it appears.

A “research use only” sales listing does not resolve regulatory uncertainty. FDA has described concerns about unapproved products, including investigational peptides. A seller’s claim is not a regulator-issued approval or assurance that the contents match a clinical-trial product. Use official evidence records to follow development; do not recreate a trial treatment from a headline. FDA safety communication.